Table 3 Treatment line progression, overall and by histologic categories
Histologic categories | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
All patients | Leiomyo-sarcomas | Undifferentiated pleomorphic Sarcoma | Liposarcomas | Vascular sarcomas | Fibroblastic/myofibroblastic sarcomas | Nerve sheath sarcomas | Rhabdomyo-sarcomas | Synovial sarcomas | Others/NOS | |
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
All patients | 4274 | 922 | 652 | 554 | 357 | 227 | 106 | 98 | 49 | 1309 |
Receiving first-line systemica treatment | 1227 (28.7) | 341 (37.0) | 158 (24.2) | 140 (25.3) | 130 (36.4) | 58 (25.6) | 24 (22.6) | 28 (28.6) | 21 (42.9) | 327 (25.0) |
Duration, mean (SD) | 4.1 (4.1) | 4.1 (4.2) | 4.4 (5.7) | 4.3 (4.7) | 4.4 (3.4) | 4.2 (3.8) | 3.3 (2.5) | 4.5 (2.9) | 3.9 (3.3) | 3.8 (3.2) |
Median | 3.0 | 3.1 | 2.6 | 3.0 | 3.5 | 3.6 | 3.1 | 3.7 | 3.0 | 2.8 |
Receiving second-line systemica treatment | 476 (11.1) | 148 (16.1) | 64 (9.8) | 45 (8.1) | 60 (16.8) | 19 (8.4) | – | 15 (15.3) | – | 109 (8.3) |
Duration, mean (SD) | 4.6 (5.3) | 4.5 (4.0) | 5.1 (8.6) | 5.5 (5.4) | 4.6 (5.2) | 4.7 (3.6) | – | 3.2 (2.2) | – | 4.3 (4.7) |
Median | 3.0 | 3.3 | 2.9 | 4.0 | 3.4 | 4.8 | – | 2.6 | – | 2.9 |
Receiving third-line systemica treatment | 189 (4.4) | 66 (7.2) | 24 (3.7) | 15 (2.7) | 21 (5.9) | – | – | – | – | 46 (3.5) |
Duration, mean (SD) | 4.0 (3.4) | 4.6 (3.6) | 3.3 (3.8) | 2.8 (2.2) | 5.1 (3.6) | – | – | – | – | 3.4 (2.8) |
Median | 3.0 | 3.7 | 2.3 | 2.1 | 5.1 | – | – | – | – | 2.6 |